Estimaciones de analistas de Wall Street para Evolus, Inc. (EOLS): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 11 |
| Mantener | 2 |
| Venta | 0 |
| Venta fuerte | 0 |
| Analistas totales | 13 |
| Calificación media (1-5) | 0.85 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.03 | ||
| 2026-08-05 | $0.01 | $-0.03 | +122.3% |
| 2026-05-04 | $-0.10 | $-0.14 | +28.6% |
| 2026-03-03 | $0.04 | $0.06 | -26.3% |
| 2025-11-05 | $-0.14 | $-0.19 | +26.3% |
| 2025-08-05 | $-0.24 | $-0.09 | -166.7% |
| 2025-05-07 | $-0.18 | $-0.10 | -80.0% |
| 2025-03-04 | $0.01 | $0.02 | -50.0% |
Ratios de valoración
| Precio / Valor contable | -17.05 |
| EV / EBITDA | -62.16 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | $34.9M | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Coste de Ventas | $326000 | $218000 | $9000 | $8.0M | $18.3M | $43.5M | $58.8M | $61.6M | $84.0M | $104.4M |
| Beneficio Bruto | -$326000 | -$218000 | -$9000 | $26.9M | $38.2M | $56.1M | $89.8M | $140.5M | $182.3M | $192.8M |
| I+D | $12.6M | $6.7M | $6.5M | $4.0M | $1.7M | $2.1M | $6.7M | $15.4M | $9.2M | $9.6M |
| Generales y Administrativos | $7.0M | $4.8M | $29.1M | $113.6M | $98.2M | $112.1M | $141.8M | $164.9M | $198.0M | $220.8M |
| Gastos Operativos | $20.0M | $11.7M | $35.6M | $125.9M | $191.3M | $100.5M | $155.1M | $189.8M | $216.7M | $230.4M |
| Beneficio Operativo | -$20.0M | -$11.7M | -$46.1M | -$98.9M | -$153.1M | -$44.4M | -$65.3M | -$49.2M | -$34.4M | -$37.6M |
| EBITDA | -$19.6M | -$11.5M | -$46.1M | -$92.1M | -$144.8M | -$39.1M | -$53.9M | -$41.8M | -$25.0M | -$22.5M |
| Gastos por Intereses | 0 | 0 | $863000 | $8.0M | $10.5M | $1.4M | $9.1M | $13.8M | $18.7M | $19.7M |
| Beneficio Antes de Impuestos | -$20.0M | -$11.7M | -$46.8M | -$105.1M | -$162.9M | -$46.8M | -$74.3M | -$61.5M | -$49.8M | -$51.0M |
| Impuestos | $93000 | -$7.3M | $65000 | -$15.0M | $77000 | $42000 | $95000 | $176000 | $664000 | $677000 |
| Beneficio Neto | -$20.1M | -$4.5M | -$46.9M | -$90.0M | -$163.0M | -$46.8M | -$74.4M | -$61.7M | -$50.4M | -$51.6M |
| BPA | $-1.08 | $-0.19 | $-1.92 | $-3.19 | $-4.83 | $-0.94 | $-1.33 | $-1.08 | $-0.81 | $-0.80 |
| BPA Diluido | $-1.08 | $-0.19 | $-1.92 | $-3.19 | $-4.83 | $-0.94 | $-1.33 | $-1.08 | $-0.81 | $-0.80 |
| Acciones en Circulación (Diluidas) | $18.6M | $23.6M | $24.4M | $28.2M | $33.7M | $49.8M | $56.1M | $56.9M | $62.0M | $64.5M |
Precio
| Precio | $7.99 |
| Capitalización | $526M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AUTL · CBLL · EHAB · KIDS · KMDA · NGNE · QSI
Explorar sector: Healthcare · Drug Manufacturers - Specialty & Generic
Más secciones de EOLS: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones